Estadístiques de A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer
Visites totals
| views | |
|---|---|
| A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer | 171 |
Visites totals per mes
| views | |
|---|---|
| July 2024 | 0 |
| August 2024 | 4 |
| September 2024 | 11 |
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
Visites al fitxer
| views | |
|---|---|
| cejalvo-esm-apha.pdf(legacy) | 155 |
| cejalvo-esm-apha.pdf | 1 |
Vistes principals per país
| views | |
|---|---|
| United States | 132 |
| Sweden | 14 |
| Germany | 5 |
| Ireland | 5 |
| China | 4 |
| Spain | 3 |
| Australia | 2 |
| Ukraine | 2 |
| France | 1 |
| Malaysia | 1 |
| Taiwan | 1 |
Visites principals per ciutat
| views | |
|---|---|
| Ashburn | 34 |
| San Ramon | 25 |
| Fairfield | 22 |
| Boardman | 10 |
| Cambridge | 9 |
| Menlo Park | 8 |
| Ann Arbor | 7 |
| Dublin | 5 |
| Mountain View | 4 |
| Shenzhen | 4 |
| San Diego | 2 |
| Andover | 1 |
| Barcelona | 1 |
| Dearborn | 1 |
| Hinojosa Del Duque | 1 |
| Hsinchu | 1 |
| Petaling Jaya | 1 |
| Sacramento | 1 |
| Stockholm | 1 |